Outcome prediction by extranodal involvement, IPI, R‐IPI, and NCCN‐IPI in the PET/CT and rituximab era: A Danish–Canadian study of 443 patients with diffuse‐large B‐cell lymphoma

Publisher： John Wiley & Sons Inc

E-ISSN： 1096-8652|90|11|1041-1046

ISSN： 0361-8609

Source： AMERICAN JOURNAL OF HEMATOLOGY, Vol.90, Iss.11, 2015-11, pp. : 1041-1046

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Increased bone marrow FDG uptake at PET/CT is not a sufficient proof of bone marrow involvement in diffuse large B‐cell lymphoma

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 9, 2015-09 ,pp. : E182-E182

John Wiley & Sons Inc

Access to resources Recommend Favorite

Weekly rituximab consolidation following four cycles of R‐CHOP induction chemotherapy in very elderly patients with diffuse large B‐cell lymphoma: Consortium for improving survival of lymphoma study (CISL)

By  

EUROPEAN JOURNAL OF HAEMATOLOGY, Vol. 94, Iss. 6, 2015-06 ,pp. : 504-510

John Wiley & Sons Inc

Access to resources Recommend Favorite

Risk‐tailored CNS prophylaxis in a mono‐institutional series of 200 patients with diffuse large B‐cell lymphoma treated in the rituximab era

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 168, Iss. 5, 2015-03 ,pp. : 654-662

John Wiley & Sons Inc

Access to resources Recommend Favorite

Radiation for diffuse large B‐cell lymphoma in the rituximab era: Analysis of the National Comprehensive Cancer Network lymphoma outcomes project

By  

CANCER, Vol. 121, Iss. 7, 2015-04 ,pp. : 1032-1039

John Wiley & Sons Inc

Access to resources Recommend Favorite

Excellent outcomes and lack of prognostic impact of cell of origin for localized diffuse large B‐cell lymphoma in the rituximab era

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 171, Iss. 5, 2015-12 ,pp. : 776-783

John Wiley & Sons Inc

Access to resources Recommend Favorite